Actively Recruiting
Biomarkers in the Retina for Prognosticating Mental Health Treatments
Led by VA Puget Sound Health Care System · Updated on 2024-04-12
50
Participants Needed
1
Research Sites
341 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Title: ERG as a potential biomarker of SSRI-responsive PTSD: A pilot study Posttraumatic stress disorder (PTSD) affects many individuals who experience a traumatic event. Previous studies suggest that there is a connection between the brain and the retina, and that the electroretinogram (ERG) may be a valuable biomarker to tell us more about signals in the brain that are related to mental health disorders like PTSD. The goal of this observational study is to examine the ERG waveform in veterans with PTSD before and after a single dose of the selective serotonin reuptake inhibitor (SSRI), sertraline. Sertraline is one of two FDA-approved medications for the treatment of PTSD. The main questions this pilot study aims to answer are: 1. How does sertraline, an SSRI, influence the ERG waveform in veterans with PTSD? 2. Is there a significant correlation between baseline ERG signals and the change in ERG following SSRI treatment? Participants will be asked to: * Undergo ERG recordings before and after a single dose of sertraline. * Provide relevant clinical information related to PTSD symptoms and treatment history. Following the initial study visits, participants will enter an optional open label phase of the study in which qualifying participants who initiate antidepressant treatment through routine clinical care will be invited back for a follow-up ERG recording.
CONDITIONS
Official Title
Biomarkers in the Retina for Prognosticating Mental Health Treatments
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Veteran of the U.S. Armed Forces
- Current diagnosis of PTSD
You will not qualify if you...
- Known diagnosis of a primary psychotic or major neurocognitive disorder
- Significant bilateral visual loss
- History of acute angle closure glaucoma
- Known inherited retinal disease
- Previous ERG deficits
- Known photosensitive epilepsy
- Known current pregnancy or lactation
- Allergy or previous adverse reaction to sertraline or SSRI
- Allergy to Sensor Strip gel
- Hepatic failure
- Damage to orbit structure or open lesion in soft tissue surrounding the eye
- Any use in the time period of at least 6 half-lives prior to baseline of sertraline or other drugs acting on serotonin and/or unwillingness to avoid these medications for the duration of the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
VA Puget Sound Health Care System
Seattle, Washington, United States, 98108
Actively Recruiting
Research Team
K
Katharine J Liang, MD, PhD
CONTACT
R
Rebecca C Hendrickson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DEVICE_FEASIBILITY
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here